Myriam Briki obtained her BSc from the University of Lausanne after spending her final year at Uppsala University (Sweden), where she was able to focus mainly on toxicological sciences. As a result, she chose to specialize in pharmacology and toxicology during her MSc back in Lausanne.
She is now doing her PhD under the direction of Prof. Sandro Carrara (EPFL) and Dr. Monia Guidi (CHUV).
Her project, carried out at the University Hospital of Lausanne (Centre Hospitalier Universitaire Vaudois - CHUV), involves the development of population pharmacokinetic (pop-PK) meta-models for conventional cytotoxic chemotherapies. Once developed and validated, these models will make it possible to predict the evolution of the plasma concentration of the drugs for patients undergoing chemotherapy in order to adjust their dosage to achieve optimal therapeutic exposure, using maximum a posteriori Bayesian estimation in the context of therapeutic drug monitoring (TDM).
Along with her thesis work, she takes part in routine clinical tasks at the Service of Clinical Pharmacology (CHUV), interpreting TDM results for anticancer and antiretroviral therapies.